XML 28 R16.htm IDEA: XBRL DOCUMENT
v3.22.1

Note 10 - Share Based Payments | 12 Months Ended
--- | ---
Dec. 31, 2021
Notes to Financial Statements |
Share-based Payment Arrangement [Text Block] | Note 10 – Share Based Payments In January 2007, our stockholders approved the Company’s 2006 Omnibus Incentive Compensation Plan, which was designed to attract, retain and motivate key employees. Under this plan, we reserved 5.1 million shares of our common stock for issuance to employees and directors through incentive stock options, non-qualified stock options or restricted stock. In June 2015 our stockholders approved a new 2015 Omnibus Incentive Compensation Plan (the “Plan”) and reserved a further 2.5 million shares of our common stock for issuance to employees and directors through incentive stock options, non-qualified stock options or restricted shares. At our 2021 Annual Meeting of Stockholders our stockholders approved an increase further 3.0 million shares of our common stock reserved for our 2015 plan. At December 31, 2021, 3,420,708 shares remain available for issuance. The Plan is administered by the compensation committee of our Board of Directors. Subject to the express provisions of the Plan, the compensation committee has the Board of Directors' authority to administer and interpret the Plan, including the discretion to determine the form of grant, exercise price, vesting schedule, contractual life and the number of shares to be issued. We have historically issued restricted stock under the Plan; however, as further incentive to key employees, the Company also issued options to purchase shares of our common stock during the year ended December 31, 2021. Stock-based Compensation Expense For the years ended December 31, 2021 and 2020, we recognized stock-based compensation of approximately $469,000 and $392,000, respectively, which was included in selling, general and administrative expenses on the accompanying Consolidated Statements of Operations. As of December 31, 2021, the total unrecognized compensation cost related to unvested restricted stock and options to purchase common stock was approximately $0.7 million with a weighted average remaining vest life of 1.67 years. Stock Options Although we had historically issued restricted stock under the Plan, we also issued options to purchase shares of our common stock during the year ended December 31, 2021. We did not grant any stock options during the year ended December 31, 2020. Option grants can have various vesting features but typically involve time-based vesting. Fair Value Determination –We utilize a Black-Scholes-Merton model to value stock options vesting over time. We will reconsider the use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that cannot be reasonably estimated under these models. Volatility -The expected volatility of the options granted was estimated based upon historical volatility of our share price through weekly observations of our trading history corresponding to the expected term for Black-Scholes-Merton model. Expected Term -Given the lack of historical experience, the expected term of options granted to employees was determined utilizing a plain vanilla approach whereby minimum or median time to vest and the contractual term of 10 years are averaged. Risk-free Interest Rate -The yield was determined based on U.S. Treasury rates corresponding to the expected term of the underlying grants. Dividend Yield -The Black-Scholes-Merton valuation model requires an expected dividend yield as an input. We currently do not anticipate paying dividends; therefore, the yield was estimated at zero. The following table summarizes weighted-average assumptions used in our calculations of fair value for stock-option grants for the year ended December 31, 2021:
Black-Scholes-Merton |
Volatility |  |  | 134 | %
Expected life of options (in years) |  |  | 5 |
Risk-free interest rate |  |  | 0.80 | %
Dividend yield |  |  | 0 | %
During the year ended December 31, 2021 we granted stock options to purchase 150,000 shares of common stock at a weighted-average exercise price of $0.46 per share, which reflected the 30-day weighted fair market value of the shares on date of grant. In accordance with the terms of the Plan, the Board of Directors determined that the average of the high and low bid prices for the Common Stock reported daily on the OTCQB marketplace on the grant date was the fair market value of the shares. The weighted-average fair value of options granted during the year ended December 31, 2021, as determined under the Black-Scholes-Merton valuation model was $0.46. The following table includes information with respect to stock option activity and stock options outstanding for the years ended December 31, 2021 and 2020:
|  |  |  |  |  |  |  |  |  | Weighted Average |  |  |  |  |
|  | Number |  |  | Weighted |  |  | Remaining |  |  | Aggregate |
|  | Of |  |  | Average |  |  | Contractual |  |  | Intrinsic |
|  | Shares |  |  | Exercise Price |  |  | Life (years) |  |  | Value* |
Shares under option, January 1, 2020 |  |  | 2,174,000 |  |  | $ | 0.27 |  |  |  | - |  |  | $ | - |
Options granted |  |  | - |  |  | $ | - |  |  |  |  |  |  |  |  |
Options exercised |  |  | (24,000 | ) |  | $ | 0.10 |  |  |  |  |  |  |  |  |
Options cancelled and expired |  |  | (250,000 | ) |  | $ | (0.10 | ) |  |  |  |  |  |  |  |
Shares under option, December 31, 2020 |  |  | 1,900,000 |  |  | $ | 0.21 |  |  |  | 5.63 |  |  |  |  |
Options granted |  |  | 150,000 |  |  | $ | 0.46 |  |  |  |  |  |  |  |  |
Options exercised |  |  | (450,000 | ) |  | $ | 0.10 |  |  |  |  |  |  |  |  |
Options cancelled and expired |  |  | (150,000 | ) |  | $ | (0.51 | ) |  |  |  |  |  |  |  |
Shares under option, December 31, 2021 |  |  | 1,450,000 |  |  | $ | 0.24 |  |  |  | 5.33 |  |  | $ | 322 |
*Aggregate intrinsic value includes only those options with intrinsic value (options where the exercise price is below the market price). The following table summarizes non-vested stock options for the years ended December 31, 2021 and 2020:
|  |  |  |  |  | Weighted |
|  | Number of |  |  | Average |
|  | Shares |  |  | Fair Value |
Non-vested stock options at January 1, 2020 |  |  | 416,667 |  |  | $ | 0.47 |
Options granted |  |  | - |  |  | $ | - |
Vested during period |  |  | (83,833 | ) |  | $ | (0.47 | )
Options cancelled |  |  | (250,000 | ) |  | $ | (0.80 | )
Non-vested shares under option, December 31, 2020 |  |  | 83,334 |  |  | $ | 0.47 |
Options granted |  |  | 150,000 |  |  | $ | 0.46 |
Vested during period |  |  | (83,334 | ) |  | $ | (0.47 | )
Options cancelled |  |  | - |  |  | $ | - |
Non-vested shares under option, December 31, 2021 |  |  | 150,000 |  |  | $ | 0.46 |
The following table includes information concerning stock options exercisable and stock options expected to vest at December 31, 2021:
|  |  |  |  |  | Weighted Average |  |  | Weighted |  |  |  |  |
|  |  |  |  |  | Remaining |  |  | Average |  |  | Aggregate |
|  |  |  |  |  | Contractual |  |  | Exercise |  |  | Intrinsic |
|  | Options |  |  | Life (years) |  |  | Price |  |  | Value |
Stock options exercisable |  |  | 1,300,000 |  |  |  | 5.63 |  |  | $ | 0.21 |  |  | $ | 322 |
Stock options expected to vest |  |  | 150,000 |  |  |  | 9.34 |  |  | $ | 0.46 |  |  | $ | - |
Options exercisable and expected to vest |  |  | 1,450,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Restricted Stock We have granted shares of restricted stock under the Plan. A restricted stock award is an issuance of shares that cannot be sold or transferred by the recipient until the vesting period lapses. Restricted shares issued to employees typically vest over two or three years in equal installments on the anniversaries of the grant date, contingent upon employment with the Company on the vesting dates. The related compensation expense is recognized over the service period and is based on the grant date fair value of the stock and the number of shares expected to vest. The fair value of restricted stock awarded for the years ended December 31, 2021 and 2020 was $9,000 and $1,225,000, respectively, and was calculated using the value of TSS’ common stock on the grant date. The value of awards are amortized over the vesting periods of the awards taking into account the effect of an estimated forfeiture rate of zero associated with termination behavior for the years ended December 31, 2021 and 2020, respectively. The following table summarizes the restricted stock activity during the years ended December 31, 2021 and 2020:
|  |  |  |  |  | Weighted Average |
|  | Number of |  |  | Grant Date |
|  | Shares |  |  | Fair Value |
Unvested January 1, 2020 |  |  | 956,000 |  |  | $ | 0.72 |
Granted restricted stock |  |  | 1,396,000 |  |  | $ | 0.88 |
Cancelled restricted stock |  |  | (225,000 | ) |  | $ | (0.81 | )
Vested restricted stock |  |  | (407,167 | ) |  | $ | (0.50 | )
Unvested December 31, 2020 |  |  | 1,720,333 |  |  | $ | 0.89 |
Granted restricted stock |  |  | 10,000 |  |  | $ | 0.85 |
Cancelled restricted stock |  |  | (49,000 | ) |  | $ | (0.68 | )
Vested restricted stock |  |  | (781,333 | ) |  | $ | (0.91 | )
Unvested December 31, 2021 |  |  | 900,000 |  |  | $ | 0.88 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration